Начало・Списък с акции・MacroGenics Inc

MacroGenics Inc

Затворен

СекторЗдравеопазване

4.28 -2.28

Купи Продай

Преглед

Промяна на цената на акция

24 ч

Текуща

Минимум

4.09

Максимум

4.43

Ключови измерители
By Trading Economics
Приходи	56M 20M
Продажби	12M 33M
EPS	-0.27
Марж на печалбата	59.439
Служители	293
EBITDA	-34M -65M

Препоръки
By TipRanks
Препоръки	Купи
12-месечна прогноза	+59.09% upside

Дивиденти
By Acuity
Следващи печалби	10.11.2026 г.

Пазарни показатели
By TradingEconomics
Пазарна капитализация	-5.2M 254M
Предишно отваряне	6.56
Предишно затваряне	4.28

Настроения в новините

By Acuity

50%

135 / 339 Класиране в Healthcare

MacroGenics Inc Графика

Миналото представяне не гарантира бъдещи резултати.

Свързани новини

31.08.2026 г., 20:02 ч. UTC

MacroGenics Inc shares are lower today amid broader market volatility linked to potential interest rate hikes. No specific company news was identified.

20.08.2026 г., 20:06 ч. UTC

MacroGenics shares are lower today, pulling back from earlier session highs amid rising crude oil prices and increased U.S. Treasury yields.

19.08.2026 г., 21:01 ч. UTC

MacroGenics Inc shares are lower in after-market trading, continuing a decline since Wednesday's close, with no specific news identified to explain the movement.

18.08.2026 г., 19:46 ч. UTC

MacroGenics Inc. shares are gaining during Tuesday's session, despite earlier pulling back from a session high amid rising Treasury yields and inflation concerns.

17.08.2026 г., 19:51 ч. UTC

MacroGenics Inc shares are lower today amid unusual volatility, having hit a session low before a brief recovery. No specific news was identified.

14.08.2026 г., 19:21 ч. UTC

Shares of MacroGenics Inc. are lower today amid cautious investor sentiment following a drop in U.S. retail sales, impacting expectations for Federal Reserve interest rate hikes.

13.08.2026 г., 21:01 ч. UTC

News

MacroGenics shares declined after reporting Q2 2026 results, which included a workforce reduction and a pro forma cash position of $327 million.

12.08.2026 г., 19:46 ч. UTC

Social Media

MacroGenics Inc received a $10 million milestone payment, boosting investor sentiment and contributing to shares trading higher during Wednesday's session.

11.08.2026 г., 22:26 ч. UTC

News

MacroGenics shares rise after Gilead Sciences exercises licensing option, triggering a $10 million payment and potential for $1.6 billion in future milestones.

4.08.2026 г., 19:46 ч. UTC

MacroGenics shares are lower today, retracing from a session high amid a broader market decline linked to falling crude oil prices.

31.07.2026 г., 20:06 ч. UTC

MacroGenics Inc. shares are lower today amid rising U.S. Treasury yields and inflation concerns, continuing a downward trend since Thursday's close.

29.07.2026 г., 20:09 ч. UTC

MacroGenics Inc shares are lower today, continuing a downward trend since Tuesday's close. The stock showed early gains before sharply reversing course.

28.07.2026 г., 17:03 ч. UTC

MacroGenics Inc shares are lower today amid broader market volatility. The stock remains near the lower end of its one-month range.

27.07.2026 г., 20:01 ч. UTC

News

MacroGenics shares are higher as analysts remain optimistic about MGC026's potential, supported by a strong cash runway projected until 2028.

24.07.2026 г., 20:01 ч. UTC

MacroGenics Inc shares are declining amid broader biotechnology sector weakness, marking four consecutive sessions of losses with no specific company news identified.

22.07.2026 г., 19:51 ч. UTC

MacroGenics Inc is trading lower today, breaking a trend of higher closes. Broader market sentiment is cautious amid rising crude oil prices and geopolitical tensions.

21.07.2026 г., 19:06 ч. UTC

MacroGenics Inc shares are higher, supported by optimism in the semiconductor sector and potential price increases from TSMC by 2027.

Сравнение с други в отрасъла

Ценова промяна

MacroGenics Inc Прогноза

Ценова цел

By TipRanks

59.09% нагоре

12-месечна прогноза

Среден 7 USD 59.09%

Висок 11 USD

Нисък 4 USD

Според 4 анализатори от Wall Street, предложили 12-месечна ценова цел за MacroGenics Inc през последните три месеца.

Консенсусна оценка

By TipRanks

Купи

4 ratings

Купи

Задържане

Продай

Според 4 анализатори, дали борсови рейтинги на MacroGenics Inc през последните 3 месеца.

Настроение

By Acuity

135 / 339 Класиране в Здравеопазване

Финанси

Продажбени и админисративни разходи

Оперативни разходи

Печалба преди облагане с данъци

Продажби

Разходи за продажби

Брутна печалба от продажби

Разходи за лихви по дълг

EBITDA

Оперативна печалба

Относно MacroGenics Inc

MacroGenics, Inc., a biopharmaceutical company, develops, manufactures, and commercializes antibody-based therapeutics to treat cancer in the United States. Its approved product is MARGENZA (margetuximab-cmkb), a human epidermal growth factor receptor 2 (HER2) receptor antagonist indicated, in combination with chemotherapy, for the treatment of adult patients with metastatic HER2-positive breast cancer who have received two or more prior anti-HER2 regimens. The company's pipeline of immuno-oncology product candidates includes MGC018, an antibody drug conjugate (ADC), which targets solid tumors expressing B7-H3; Enoblituzumab, a monoclonal antibody that targets B7-H3; and MGD024, an investigational bispecific CD123 × CD3 DART molecule to minimize cytokine-release syndrome for patients with hematologic malignancies. In addition, it develops Lorigerlimab, a monoclonal antibody that targets the immune checkpoints PD-1 and cytotoxic T-lymphocyte-associated protein 4; Tebotelimab, an investigational tetravalent DART molecule for PD-1 and lymphocyte-activation gene 3; Retifanlimab, a humanized monoclonal antibody targeting programmed death receptor-1; and IMGC936, an ADC that targets ADAM9, a cell surface protein over-expressed in various solid tumor types. Further, the company develops MGD014 and MGD020, a DART molecule to target the envelope protein of human immunodeficiency virus infected cells and CD3 on T cells; Teplizumab for the treatment of type 1 diabetes; and PRV-3279, a CD32B × CD79B DART molecule for the treatment of autoimmune indications. It has collaborations with Incyte Corporation; Zai Lab Limited; I-Mab Biopharma; and Janssen Biotech, Inc. The company was incorporated in 2000 and is headquartered in Rockville, Maryland.